 |
|
|
| |
Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection
|
| |
| |
Reported by Jules Levin
AASLD Nov 7-11 2014 Boston
Man-Fung Yuen1, Henry Lik Yuen Chan2, Bruce D. Given3, James Hamilton3, Thomas Schluep3, David L. Lewis3, Ching-Lung Lai1, Stephen A. Locarnini4, Johnson YN Lau5, Robert G. Gish6,7 1 The University of Hong Kong, Hong Kong, China; 2 The Chinese University of Hong Kong, Hong Kong, China; 3 Arrowhead Research Corporation, Pasadena, CA, USA; 4 Victorian Infectious Diseases Reference Laboratory, Victoria, Australia; 5 Hong Kong Polytechnic University, Hong Kong, China; 6 Stanford University, Palo Alto, CA, USA; 7 Hepatitis B Foundation, Doylestown, PA, USA
|
| |
|
|
|
|
|
